Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (651)	1/6/2001 9:06:34 PM
From: Spekulatius	Read Replies (1) \| Respond to of 666

V1 what do you think is the market potential for Bexxar? After the merger with CRXA, the combined entity has a market cap of more than 850M$ (at a stock price of 21$). Somewhere I read that the market potential for Bexxar is 100M$ only, so this would not be enough for leverage for the company after the merger,IMHO, especially since it will take years to get market acceptance for hot antibodies. CRXA seems to have a broad pipeline but only mediocre quality. Melacine has only marginal efficacy and will probably never be approved in the USA. What are your thoughts of the new CRXA?